206 related articles for article (PubMed ID: 20021330)
1. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations.
Pauwels K; Gijsbers R; Toelen J; Schambach A; Willard-Gallo K; Verheust C; Debyser Z; Herman P
Curr Gene Ther; 2009 Dec; 9(6):459-74. PubMed ID: 20021330
[TBL] [Abstract][Full Text] [Related]
2. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
3. Biosafety of lentiviral vectors.
Debyser Z
Curr Gene Ther; 2003 Dec; 3(6):517-25. PubMed ID: 14683448
[TBL] [Abstract][Full Text] [Related]
4. Gene delivery by lentivirus vectors.
Cockrell AS; Kafri T
Mol Biotechnol; 2007 Jul; 36(3):184-204. PubMed ID: 17873406
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
6. Novel bovine lentiviral vectors based on Jembrana disease virus.
Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
[TBL] [Abstract][Full Text] [Related]
7. Lentiviruses in gene therapy clinical research.
Connolly JB
Gene Ther; 2002 Dec; 9(24):1730-4. PubMed ID: 12457288
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.
Vigna E; Naldini L
J Gene Med; 2000; 2(5):308-16. PubMed ID: 11045424
[TBL] [Abstract][Full Text] [Related]
9. Biosafety features of lentiviral vectors.
Schambach A; Zychlinski D; Ehrnstroem B; Baum C
Hum Gene Ther; 2013 Feb; 24(2):132-42. PubMed ID: 23311447
[TBL] [Abstract][Full Text] [Related]
10. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications.
Kumar P; Woon-Khiong C
Curr Gene Ther; 2011 Apr; 11(2):144-53. PubMed ID: 21291355
[TBL] [Abstract][Full Text] [Related]
11. Strategies for retargeted gene delivery using vectors derived from lentiviruses.
Bartosch B; Cosset FL
Curr Gene Ther; 2004 Dec; 4(4):427-43. PubMed ID: 15578992
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research.
Schambach A; Galla M; Modlich U; Will E; Chandra S; Reeves L; Colbert M; Williams DA; von Kalle C; Baum C
Exp Hematol; 2006 May; 34(5):588-92. PubMed ID: 16647564
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral vectors: optimization of packaging, transduction and gene expression.
Delenda C
J Gene Med; 2004 Feb; 6 Suppl 1():S125-38. PubMed ID: 14978756
[TBL] [Abstract][Full Text] [Related]
14. Transient Expression of Green Fluorescent Protein in Integrase-Defective Lentiviral Vector-Transduced 293T Cell Line.
Nordin F; Hamid ZA; Chan L; Farzaneh F; Hamid MK
Methods Mol Biol; 2016; 1448():159-73. PubMed ID: 27317180
[TBL] [Abstract][Full Text] [Related]
15. Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.
Sachdeva G; D'Costa J; Cho JE; Kachapati K; Choudhry V; Arya SK
J Med Virol; 2007 Feb; 79(2):118-26. PubMed ID: 17177309
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
17. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
18. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
19. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
20. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
